English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Subcutaneous immunotherapy (SCIT) is an established recommended treatment for allergic asthma. SCIT provides symptomatic relief, and it is potentially curative. Its build-up phase represents vital information to improve patient compliance and treatment outcomes. Aim: This study aims to assess the build-up phase outcomes of subcutaneous immunotherapy (SCIT) for pediatric allergic asthma. Methods: The retrospective cohort study comprised 65 children with allergic asthma due to house dust mites at the end of initial build-up phase of SCIT (3 months) from 2009 until 2012 at one hospital in Surabaya, Indonesia. Pre-SCIT clinical evaluation included skin prick tests for Der p 1 and Der f 1, eosinophil counts test, and the reversibility of forced expiratory volume in a second. The serum level of IFN-γ (TH1), IL-4 (TH2), TGF-β (Tregs), and IL-17 (TH17) were measured via enzyme-linked immunosorbent assays (ELISA) at the end of the initial build-up phase of SCIT. Results: Of the 65 samples, 48 (73.8%) exhibited significant improvement after three months, including 37 (56.9%) partially controlled asthma as against 11 (16.9%) controlled one, respectively. Eosinophil counts, IL-4, and IL-17 levels were higher among subjects who did not have an improvement, whereas they showed lower IFN-γ levels and smaller wheal diameters for either Der p 1 or Der f 1. Total IgE and TGF-β levels were not significantly different according to the asthma refinement. Conclusion: At the end of the build-up phase, SCIT facilitated improvement in most subjects with allergic asthma, and the outcome was associated with eosinophil counts, wheal diameters for Der p 1 and Der f 1, as well as IFN-γ, IL-4, and IL-17 levels.

The build-up phase outcome of subcutaneous immunotherapy for pediatric allergic asthma: A retrospective cohort study from Surabaya, Indonesia